001     143571
005     20251110151200.0
024 7 _ |a 10.1002/ijc.32400
|2 doi
024 7 _ |a pmid:31081944
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:60429106
|2 altmetric
037 _ _ |a DKFZ-2019-01151
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Varon, Mor
|b 0
245 _ _ |a The long non-coding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells.
260 _ _ |a Bognor Regis
|c 2019
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1762783900_2549714
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #DKFZ-MOST-Ca171#
520 _ _ |a Medulloblastoma is the most common malignant brain cancer in children. Since previous studies have mainly focused on alterations in the coding genome, our understanding of the contribution of long non-coding RNAs (lncRNAs) to medulloblastoma biology is just emerging. Using patient-derived data, we show that the promoter of lncRNA TP73-AS1 is hypomethylated and that the transcript is highly expressed in the SHH subgroup. Furthermore, high expression of TP73-AS1 is correlated with poor outcome in patients with TP53 wild type SHH tumors. Silencing TP73-AS1 in medulloblastoma tumor cells induced apoptosis, while inhibited proliferation and migration were inhibited in culture. In vivo, silencing TP73-AS1 in medulloblastoma tumor cells resulted in reduced tumor growth, reduced proliferation of tumor cells, increased apoptosis leading to reduced survival of tumor bearing mice. Together, our study suggest that the lncRNA TP73-AS1 is a prognostic marker and therapeutic target in medulloblastoma tumors and serves as a proof of concept that lncRNAs are important factors in the disease. This article is protected by copyright. All rights reserved.
536 _ _ |a 899 - ohne Topic (POF3-899)
|0 G:(DE-HGF)POF3-899
|c POF3-899
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Levy, Tal
|b 1
700 1 _ |a Mazor, Gal
|b 2
700 1 _ |a Ben David, Hila
|b 3
700 1 _ |a Marciano, Ran
|b 4
700 1 _ |a Kerlin, Yakov
|b 5
700 1 _ |a Prasad, Manu
|b 6
700 1 _ |a Elkabets, Moshe
|0 0000-0003-3634-9098
|b 7
700 1 _ |a Pauck, David
|0 P:(DE-He78)964e19ad88fd6ff751ae2c10599ad7cc
|b 8
|u dkfz
700 1 _ |a Ahmadov, Ulvi
|0 P:(DE-He78)87bc8fe0f11339b1fac47821a539bdb3
|b 9
|u dkfz
700 1 _ |a Picard, Daniel
|0 P:(DE-He78)2d0b899984e41ffa8cb15d799d32afd1
|b 10
|u dkfz
700 1 _ |a Qin, Nan
|0 P:(DE-He78)a05fe89e8d9ccc1fbd56df77464c7856
|b 11
|u dkfz
700 1 _ |a Borkhardt, Arndt
|b 12
700 1 _ |a Reifenberger, Guido
|b 13
700 1 _ |a Leprivier, Gabriel
|b 14
700 1 _ |a Remke, Marc
|0 P:(DE-He78)a244aa021112b9002419791434bbc71c
|b 15
|u dkfz
700 1 _ |a Rotblat, Barak
|0 0000-0003-2985-7115
|b 16
773 _ _ |a 10.1002/ijc.32400
|g p. ijc.32400
|0 PERI:(DE-600)1474822-8
|n 12
|p 3402-3413
|t International journal of cancer
|v 145
|y 2019
|x 1097-0215
909 C O |p VDB
|o oai:inrepo02.dkfz.de:143571
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)964e19ad88fd6ff751ae2c10599ad7cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)87bc8fe0f11339b1fac47821a539bdb3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)2d0b899984e41ffa8cb15d799d32afd1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)a05fe89e8d9ccc1fbd56df77464c7856
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)a244aa021112b9002419791434bbc71c
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF3-890
|0 G:(DE-HGF)POF3-899
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2017
920 1 _ |0 I:(DE-He78)L401-20160331
|k L401
|l DKTK Essen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)L401-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21